THERAPEUTIC AND PROPHYLACTIC USE OF FRAXI PARIN AGAINST THROMBOEMBOLISM IN PATIENTS WITH HEPARIN-INDUCED THROMBOCYTOPENIA

Seventeen patients aged 26-52 with recurrent thromboembolism of the ve ins and disturbances of cerebral and coronary circulation (3 and 2 cas es, respectively) treated by unfractionated heparin developed thromboc ytopenia in the presence of enhanced platelet aggregation. Despite hep arin therapy, fresh thrombi of different sties appeared in 5 patients. A cross to fraxiparin (France) resulted in correction of thrombocytop enia, normalization of spontaneous platelet aggregation in two thirds of the patients. In 5 patients thrombocytopenia persisted. It is state d that in most cases low-molecular heparin allows continuation of anti thrombotic therapy in heparin-induced thrombocytopenia. Neither transp lacental passage nor hemostatic abnormalities in the newborns were rec orded after administration of fraxiparin to 6 pregnant women.